Calcimedica, INC Form 4 insider transactions

CalciMedica's Chief Business Officer, Eric W. Roberts, increased his beneficial ownership through open market purchases of common stock.

CalciMedica's Chief Business Officer and Director, Eric W. Roberts, increased his beneficial ownership by purchasing 3,508 shares of common stock.

CalciMedica's Chief Business Officer, Eric W. Roberts, increased his beneficial ownership through open market purchases and option exercises.

CalciMedica's Chief Medical Officer, Sudarshan Hebbar, purchased 9,563 shares of common stock at an average price of $2.8194.

CalciMedica's Chief Business Officer, Eric W. Roberts, increased his beneficial ownership through a direct purchase of common stock.

CalciMedica's Chief Medical Officer, Sudarshan Hebbar, acquired additional common stock in open market transactions.

CalciMedica's Chief Scientific Officer, Kenneth A. Stauderman, reported recent stock transactions, including a sale by his spouse that resulted in a short-swing profit violation requiring repayment to the company.

CalciMedica's Chief Business Officer, Director, and 10% Owner, Eric W. Roberts, acquired 1,500 shares of common stock, signaling increased insider confidence.

CalciMedica's Chief Business Officer and Director, Eric W. Roberts, acquired 1,500 shares of common stock, signaling increased insider confidence.

CalciMedica, Inc. CEO and 10% owner Rachel Leheny has filed a Form 4 indicating a planned future purchase of 1,000 shares of common stock at $3.40 per share on July 21, 2025, under a Rule 10b5-1 trading plan.

CalciMedica, Inc. Director Robert N. Wilson acquired 4,500 shares of common stock for $2.87 per share, increasing his direct beneficial ownership to 422,029 shares.

CalciMedica's Chief Business Officer, Eric W. Roberts, a Director and 10% owner, acquired 2,000 shares of common stock at $2.88 per share.

Eric W. Roberts, CalciMedica's Chief Business Officer, Director, and 10% owner, acquired 6,500 shares of common stock, signaling increased insider confidence.

CalciMedica, Inc.'s Chief Executive Officer, Rachel Leheny, reported a planned acquisition of 2,500 shares of common stock at $2.47 per share, effective July 14, 2025, under a Rule 10b5-1 plan.

Eric W. Roberts, CalciMedica's Chief Business Officer and a 10% owner, acquired 5,000 shares of common stock through a pre-arranged trading plan.

Kenneth A. Stauderman, Chief Scientific Officer of CalciMedica, Inc., reported an indirect acquisition of 1,000 shares of common stock by his spouse at a price of $1.85 per share.

Eric W. Roberts, Chief Business Officer, Director, and 10% Owner of CalciMedica, Inc., purchased 4,500 shares of common stock for approximately $6,482.70, increasing his total beneficial ownership to 997,410 shares.

CalciMedica, Inc.'s Chief Medical Officer, Sudarshan Hebbar, was granted 83,300 employee stock options with an exercise price of $1.53 per share, following stockholder approval of an amended equity incentive plan.

CalciMedica, Inc.'s Chief Financial Officer, Stephen Bardin, has reported an acquisition of 2,000 shares of common stock and a grant of 20,000 employee stock options, signaling increased insider ownership.

CalciMedica, Inc. has reported that its Chief Scientific Officer, Kenneth A. Stauderman, was granted 47,125 employee stock options with an exercise price of $1.53, following stockholder approval of an amended equity incentive plan.

CalciMedica, Inc. Chief Business Officer Eric W. Roberts was granted 72,750 employee stock options with an exercise price of $1.53, following shareholder approval of the company's amended equity incentive plan.

CalciMedica, Inc.'s President and COO, Michael J. Dunn, was granted 47,125 employee stock options following stockholder approval of an amended equity incentive plan.

CalciMedica, Inc. CEO A. Rachel Leheny was granted 77,625 employee stock options with an exercise price of $1.53 per share, following shareholder approval of an amendment to the company's 2023 Equity Incentive Plan.

CalciMedica, Inc. (CALC) has reported that Director Frederic Guerard was granted 40,000 stock options following stockholder approval of an amended equity incentive plan.

CalciMedica, Inc. Director Alan Glicklich was granted a total of 39,166 stock options with exercise prices of $1.53 and $1.65, following stockholder approval of the company's amended equity incentive plan.

CalciMedica, Inc. Director Allan Shaw was granted a total of 54,844 stock options with exercise prices of $1.53 and $1.65, following the company's stockholder approval of an amended equity incentive plan.

CalciMedica, Inc. Director Robert N. Wilson was granted a total of 68,593 stock options with exercise prices of $1.53 and $1.65, following stockholder approval of the Amended 2023 Equity Incentive Plan.

CalciMedica, Inc. (CALC) reported that Director and 10% Owner Fred A. Middleton was granted a total of 46,249 stock options on June 24, 2025, following shareholder approval of the Amended 2023 Equity Incentive Plan.

Eric W. Roberts, CalciMedica's Chief Business Officer, Director, and 10% Owner, acquired 5,000 shares of common stock, signaling increased insider confidence.

Eric W. Roberts, CalciMedica's Chief Business Officer, Director, and 10% Owner, reported recent purchases of common stock totaling 10,100 shares, signaling increased insider confidence.